FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3210368009> ?p ?o ?g. }

• W3210368009 endingPage "e2129647" @default.
• W3210368009 startingPage "e2129647" @default.
• W3210368009 abstract "<h3>Importance</h3> Randomized clinical trials in prostate cancer have reported noninferior outcomes for hypofractionated radiation therapy (HRT) compared with conventional RT (CRT); however, uptake of HRT across jurisdictions is variable. <h3>Objective</h3> To evaluate the use of HRT vs CRT in men with nonmetastatic prostate cancer and compare patient-reported outcomes (PROs) at a population level. <h3>Design, Setting, and Participants</h3> Registry-based cohort study from the Australian and New Zealand Prostate Cancer Outcomes Registry (PCOR-ANZ). Participants were men with nonmetastatic prostate cancer treated with primary RT (excluding brachytherapy) from January 2016 to December 2019. Data were analyzed in March 2021. <h3>Exposures</h3> HRT defined as 2.5 to 3.3 Gy and CRT defined as 1.7 to 2.3 Gy per fraction. <h3>Main Outcomes and Measures</h3> Temporal trends and institutional, clinicopathological, and sociodemographic factors associated with use of HRT were analyzed. PROs were assessed 12 months following RT using the Expanded Prostate Cancer Index Composite (EPIC)–26 Short Form questionnaire. Differences in PROs were analyzed by adjusting for age and National Comprehensive Cancer Network risk category. <h3>Results</h3> Of 8305 men identified as receiving primary RT, 6368 met the inclusion criteria for CRT (n = 4482) and HRT (n = 1886). The median age was 73.1 years (IQR, 68.2-77.3 years), 2.6% (168) had low risk, 45.7% (2911) had intermediate risk, 44.5% (2836) had high-/very high–risk, and 7.1% (453) had regional nodal disease. Use of HRT increased from 2.1% (9 of 435) in the first half of 2016 to 52.7% (539 of 1023) in the second half of 2019, with lower uptake in the high-/very high–risk (1.9% [4 of 215] to 42.4% [181 of 427]) compared with the intermediate-risk group (2.2% [4 of 185] to 67.6% [325 of 481]) (odds ratio, 0.26; 95% CI, 0.15-0.45). Substantial variability in the use of HRT for intermediate-risk disease remained at the institutional level (median 53.3%; range, 0%-100%) and clinician level (median 57.9%; range, 0%-100%) in the last 2 years of the study period. There were no clinically significant differences across EPIC-26 urinary and bowel functional domains or bother scores. <h3>Conclusions and Relevance</h3> In this cohort study, use of HRT for prostate cancer increased substantially from 2016. This population-level data demonstrated clinically equivalent PROs and supports the continued implementation of HRT into routine practice. The wide variation in practice observed at the jurisdictional, institutional, and clinician level provides stakeholders with information that may be useful in targeting implementation strategies and benchmarking services." @default.
• W3210368009 created "2021-11-08" @default.
• W3210368009 creator A5004284053 @default.
• W3210368009 creator A5007949766 @default.
• W3210368009 creator A5018741301 @default.
• W3210368009 creator A5021943155 @default.
• W3210368009 creator A5026470588 @default.
• W3210368009 creator A5028347498 @default.
• W3210368009 creator A5055591728 @default.
• W3210368009 creator A5059592120 @default.
• W3210368009 creator A5070759426 @default.
• W3210368009 creator A5074661336 @default.
• W3210368009 creator A5074927555 @default.
• W3210368009 creator A5079023861 @default.
• W3210368009 creator A5081023755 @default.
• W3210368009 creator A5081744986 @default.
• W3210368009 date "2021-11-01" @default.
• W3210368009 modified "2023-10-12" @default.
• W3210368009 title "Evaluation of Hypofractionated Radiation Therapy Use and Patient-Reported Outcomes in Men With Nonmetastatic Prostate Cancer in Australia and New Zealand" @default.
• W3210368009 cites W2017622807 @default.
• W3210368009 cites W2035429331 @default.
• W3210368009 cites W2054680137 @default.
• W3210368009 cites W2188246217 @default.
• W3210368009 cites W2276901723 @default.
• W3210368009 cites W2337386322 @default.
• W3210368009 cites W2404339385 @default.
• W3210368009 cites W2465092116 @default.
• W3210368009 cites W2603384438 @default.
• W3210368009 cites W2610334119 @default.
• W3210368009 cites W2800435078 @default.
• W3210368009 cites W2803145828 @default.
• W3210368009 cites W2897539375 @default.
• W3210368009 cites W2908356299 @default.
• W3210368009 cites W2944589717 @default.
• W3210368009 cites W2952903287 @default.
• W3210368009 cites W2957230050 @default.
• W3210368009 cites W2998041096 @default.
• W3210368009 cites W3005345304 @default.
• W3210368009 cites W3009841491 @default.
• W3210368009 cites W3013800047 @default.
• W3210368009 cites W3082596999 @default.
• W3210368009 cites W3119203800 @default.
• W3210368009 cites W3121106711 @default.
• W3210368009 cites W4251629561 @default.
• W3210368009 doi "https://doi.org/10.1001/jamanetworkopen.2021.29647" @default.
• W3210368009 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8561328" @default.
• W3210368009 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34724555" @default.
• W3210368009 hasPublicationYear "2021" @default.
• W3210368009 type Work @default.
• W3210368009 sameAs 3210368009 @default.
• W3210368009 citedByCount "9" @default.
• W3210368009 countsByYear W32103680092022 @default.
• W3210368009 countsByYear W32103680092023 @default.
• W3210368009 crossrefType "journal-article" @default.
• W3210368009 hasAuthorship W3210368009A5004284053 @default.
• W3210368009 hasAuthorship W3210368009A5007949766 @default.
• W3210368009 hasAuthorship W3210368009A5018741301 @default.
• W3210368009 hasAuthorship W3210368009A5021943155 @default.
• W3210368009 hasAuthorship W3210368009A5026470588 @default.
• W3210368009 hasAuthorship W3210368009A5028347498 @default.
• W3210368009 hasAuthorship W3210368009A5055591728 @default.
• W3210368009 hasAuthorship W3210368009A5059592120 @default.
• W3210368009 hasAuthorship W3210368009A5070759426 @default.
• W3210368009 hasAuthorship W3210368009A5074661336 @default.
• W3210368009 hasAuthorship W3210368009A5074927555 @default.
• W3210368009 hasAuthorship W3210368009A5079023861 @default.
• W3210368009 hasAuthorship W3210368009A5081023755 @default.
• W3210368009 hasAuthorship W3210368009A5081744986 @default.
• W3210368009 hasBestOaLocation W32103680091 @default.
• W3210368009 hasConcept C121608353 @default.
• W3210368009 hasConcept C126322002 @default.
• W3210368009 hasConcept C143998085 @default.
• W3210368009 hasConcept C167135981 @default.
• W3210368009 hasConcept C2777416452 @default.
• W3210368009 hasConcept C2778527826 @default.
• W3210368009 hasConcept C2780192828 @default.
• W3210368009 hasConcept C2908647359 @default.
• W3210368009 hasConcept C29456083 @default.
• W3210368009 hasConcept C509974204 @default.
• W3210368009 hasConcept C71924100 @default.
• W3210368009 hasConcept C72563966 @default.
• W3210368009 hasConcept C99454951 @default.
• W3210368009 hasConceptScore W3210368009C121608353 @default.
• W3210368009 hasConceptScore W3210368009C126322002 @default.
• W3210368009 hasConceptScore W3210368009C143998085 @default.
• W3210368009 hasConceptScore W3210368009C167135981 @default.
• W3210368009 hasConceptScore W3210368009C2777416452 @default.
• W3210368009 hasConceptScore W3210368009C2778527826 @default.
• W3210368009 hasConceptScore W3210368009C2780192828 @default.
• W3210368009 hasConceptScore W3210368009C2908647359 @default.
• W3210368009 hasConceptScore W3210368009C29456083 @default.
• W3210368009 hasConceptScore W3210368009C509974204 @default.
• W3210368009 hasConceptScore W3210368009C71924100 @default.
• W3210368009 hasConceptScore W3210368009C72563966 @default.
• W3210368009 hasConceptScore W3210368009C99454951 @default.
• W3210368009 hasIssue "11" @default.
• W3210368009 hasLocation W32103680091 @default.
• W3210368009 hasLocation W32103680092 @default.

• next